US imposes 100% tariff on imported patented pharmaceuticals, targeting Australia and global exporters
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025, under national security powers, bypassing a February Supreme Court ruling that struck down his broader 'Liberation Day' tariffs. The move targets Australia’s $US1.3 billion annual pharmaceutical exports, primarily from CSL, which has invested heavily in US manufacturing to mitigate risks. The tariff applies only to patented drugs, excluding generics, and offers reduced rates (20%) or exemptions (0%) for companies relocating production to the US or securing 'most favoured nation' drug pricing deals. Australia’s Pharmaceutical Benefits Scheme (PBS), which keeps drug prices lower than in the US, has drawn criticism from the Trump administration for allegedly undermining global pricing parity. Health Minister Mark Butler firmly rejected negotiations on the PBS, calling it a cornerstone of Australia’s healthcare system. While CSL may qualify for exemptions due to its US factories and plasma-derived therapies, smaller exporters face uncertainty. Other countries like the EU, Japan, and the UK secured lower tariffs (10-15%) through trade deals, highlighting Australia’s lack of a preferential arrangement. The tariff reflects Trump’s broader push to re-shore pharmaceutical production, with 120 days given to major companies to announce re-shoring plans or pricing concessions. Opposition Leader Angus Taylor pledged bipartisan support to overturn the tariffs or secure exemptions, while the Albanese government vowed to defend the PBS and study the impact on exporters.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025, under Section 232 of the Trade Expansion Act (NEWSCOMAU, SMH, THEAGE, GUARDIAN, ABC).
- Australia exported $US1.32 billion ($US1.3 billion in ABC) in pharmaceuticals to the US in 2025, with CSL accounting for the bulk of these exports (NEWSCOMAU, ABC).
- CSL has US manufacturing facilities in Illinois and North Carolina, with a $US2.2 billion ($US1.5 billion in SMH/THEAGE) expansion announced in March 2025 for its Illinois plant, set to complete by 2031 (NEWSCOMAU, SMH, THEAGE, GUARDIAN).
- The tariff applies to patented products only, excluding generic medicines (NEWSCOMAU, ABC).
- Companies moving production to the US can reduce tariffs to 20%, and those securing 'most favoured nation' drug pricing deals can avoid tariffs entirely (NEWSCOMAU, SMH, THEAGE, GUARDIAN, ABC).
- Australia’s Pharmaceutical Benefits Scheme (PBS) subsidizes drug prices lower than those in the US, which the Trump administration has criticized as undermining 'most favoured nation' pricing rules (NEWSCOMAU, GUARDIAN, ABC).
- Health Minister Mark Butler stated Australia would not negotiate changes to the PBS, calling it 'not for sale' (NEWSCOMAU, GUARDIAN, ABC).
- The US Supreme Court ruled in February 2025 that Trump’s 'Liberation Day' tariffs were illegal, but the pharmaceutical tariffs were enacted under different legislation and are unaffected (NEWSCOMAU, SMH, THEAGE, ABC).
- Japan, EU, South Korea, Switzerland, and Liechtenstein face 15% tariffs, while the UK secured a 10% tariff with potential for future reductions (NEWSCOMAU, SMH, THEAGE).
- CSL’s plasma-derived therapies (used for rare autoimmune diseases and blood-clotting disorders) may qualify for exemptions if they meet 'urgent US health needs' or are produced in countries with US trade deals (NEWSCOMAU, SMH, THEAGE).
- Large pharmaceutical companies have 120 days to announce re-shoring plans or pricing deals to avoid tariffs, while smaller firms have 180 days (SMH, GUARDIAN, ABC).
- Australia and the US have a 20-year-old free trade agreement governing pharmaceutical exports (NEWSCOMAU, SMH, THEAGE).
- Opposition Leader Angus Taylor pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters (NEWSCOMAU, SMH, THEAGE, GUARDIAN, ABC)
Points of Difference
Details reported by only one source:
- The US Supreme Court ruled in February that Trump’s 'liberation day' tariffs were illegal, but the pharmaceutical tariffs were enacted under Section 232 of the Trade Expansion Act, not emergency powers (NEWSCOMAU).
- A White House official stated pharmaceutical companies could negotiate deals with the White House to lower US prices and avoid tariffs (NEWSCOMAU).
- The tariff applies to patented products, not generic medicines, and CSL’s US-made products may be carved out due to its factories in Illinois and North Carolina (NEWSCOMAU).
- The tariff announcement was timed to mark one year since Trump’s 'Liberation Day' tariffs (NEWSCOMAU).
- The executive order mentions AstraZeneca, Johnson & Johnson, and Pfizer as major companies affected by the tariffs (NEWSCOMAU).
- 'Most favoured nation' rules under the edict force companies to lower US prices to match those in 'comparably developed nations' or face regulatory enforcement (NEWSCOMAU).
- Medicines Australia warned that 'most favoured nation' rules are hampering new medicine imports to Australia, with companies delaying launches due to low PBS prices (NEWSCOMAU).
- The tariff adjustment for steel-containing products was mentioned: if a product has less than 15% steel, the additional tariff is set to zero; if it exceeds 15%, the steel tariff is 25% of the total value (NEWSCOMAU).
- The tariff announcement was timed to mark one year since Trump’s 'Liberation Day' tariffs (SMH).
- A White House official said CSL would need to submit its re-shoring plan to the US Commerce Department for exemption consideration (SMH).
- The tariff adjustment for steel-containing products was mentioned: if a product has less than 15% steel, the additional tariff is set to zero; if it exceeds 15%, the steel tariff is 25% of the total value (SMH).
- The UK has a 10% tariff with room to go to zero in the future (SMH).
- The tariff adjustment for steel-containing products was mentioned: if a product has less than 15% steel, the additional tariff is set to zero; if it exceeds 15%, the steel tariff is 25% of the total value (THEAGE).
- The tariff announcement was timed to mark one year since Trump’s 'Liberation Day' tariffs (THEAGE).
- The tariff announcement was timed to mark one year since Trump’s 'Liberation Day' tariffs (GUARDIAN).
- Communications Minister Anika Wells stated the tariff decision was disappointing but emphasized the PBS is 'not for sale' (GUARDIAN).
- CSL’s spokesperson stated the company was reviewing information but did not anticipate material impact from tariffs, citing US-sourced plasma and $1.5 billion expansion plans (GUARDIAN).
- Trump previously suggested the tariff could be as high as 200% (ABC).
- A senior administration official stated that too many drugs 'driven by research and development here in America' are now produced abroad, making the US 'beholden to these other countries' (ABC).
- The tariff is being implemented under Section 232 of trade law to protect national security, ensuring a secure supply of drugs during conflicts or emergencies (ABC).
- CSL’s social media post in September 2024 suggested the tariff would take effect from October 2024, but the company stated it did not expect material impact (ABC).
- The US has already negotiated 17 deals worth hundreds of billions of dollars to move manufacturing to the US (ABC).
Contradictions
Conflicting information between sources:
- NEWSCOMAU states Australia exported $US1.32 billion in pharmaceuticals to the US in 2025, while ABC reports $US1.3 billion (a 10% difference).
- NEWSCOMAU reports CSL’s US factory expansion is $US2.2 billion, while SMH and THEAGE report $US1.5 billion ($2.17 billion AUD).
- NEWSCOMAU mentions AstraZeneca, Johnson & Johnson, and Pfizer as major companies affected by the tariffs, but SMH and THEAGE do not specify these companies.
- ABC states Trump previously suggested the tariff could be as high as 200%, but this detail is not mentioned in NEWSCOMAU, SMH, THEAGE, or GUARDIAN.
- SMH and THEAGE mention the UK has a 10% tariff with room to go to zero, while NEWSCOMAU states the UK has a 10% tariff but does not mention potential future reductions.
Source Articles
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....